health canada approval zepbound tirzepatide obesity canada date 🇨🇦 has approved for the treatment of obstructive sleep apnea in adults living with obesity, making it the first and only GLP-1 medication in approved for the sleep Lilly releases Zepbound® (tirzepatide) single-dose

456.44 (EPCS): Floridas Electronic Prescribing of Controlled Substances law mandates electronic prescribing for Schedule II controlled substances

45 A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2) demonstrated noninferiority or superiority of tirzepatide at all doses (5 mg, 10 mg, 15 mg) compared with semaglutide 1 mg as an add-on therapy to metformin with respect to the mean change in HbA 1c level and weight loss from baseline to 40 weeks

This characteristic sets Semaglutide apart by offering individuals the potential to maintain their achieved weight loss goals

Abstract Previous studies have shown that the risk of malignant transformation of endometriosis in premenopausal women is approximately 1%, significantly impacting the overall well-being and quality of life of affected women